NYC Healthcare News



Positive results from Phase I clinical trial of GLYX-13 presented at NCDEU meeting

October 02, 2015

The GLYX-13 Phase I trial was a randomized, double-blind, placebo-controlled single ascending dose level study of the safety, tolerability and pharmacokinetics of four dose levels of GLYX-13 in healthy volunteers.  The primary outcome measures encompassed observational and laboratory safety parameters, including schizophrenia-like side effects.  Adverse events for subjects receiving placebo and GLYX-13 were all rated as mild.  No schizophrenia-like side effects were observed, even following administration of single doses of GLYX-13 that were 10-times higher than the expected therapeutic dose based on data from animal studies.  The pharmacokinetics of GLYX-13 demonstrated similar or greater drug exposure in humans than in animals at the same doses.

NCDEU is a scientific meeting that focuses on the latest developments in psychopharmacologic clinical research and related methodology in the field of mental health.  It is co-sponsored by the National Institute of Mental Health and the American Society of Clinical Psychopharmacology and brings together over 1200 academic and industry investigators, research pharmacists and clinicians.  The NCDEU 50th Anniversary Meeting is being held June 14??June 17, 2010, at the Boca Raton Hotel in Boca Raton, Florida.  

SOURCE Naurex, Inc.